Question 1

What is Pfizer's obesity drug called?

Accepted Answer

The candidate in the Blackstone agreement is berobenatide, also identified as PF-08653944 and formerly MET-097i. Pfizer is studying weekly and monthly injection regimens. It is investigational, not an approved monthly obesity medicine.

Question 2

Did Blackstone buy Pfizer's obesity drug?

Accepted Answer

No. Pfizer's November 11 announcement says Blackstone does not acquire rights or ownership in berobenatide. Blackstone-managed funds may cover up to $1.5 billion of development costs through 2028 and become eligible for conditional, multiyear milestone payments. Pfizer retains clinical decisions and control.

Question 3

When will Pfizer's monthly weight-loss drug be approved?

Accepted Answer

No approval date has been announced. The registered monthly Phase 3 VESPER-6 trial estimates primary completion on May 4, 2028. A study completion estimate is not an FDA review schedule, and results, filing and agency decision would be separate steps.

Question 4

Will the Blackstone deal make weight-loss drugs cheaper?

Accepted Answer

The agreement provides development funding, not a public patient-price or insurance-coverage commitment. Future out-of-pocket cost would depend on any approved product's price, reimbursement and the patient's coverage. The financing alone cannot establish a lower prescription cost.

Question 5

Why does Pfizer need Blackstone to fund obesity trials?

Accepted Answer

Pfizer has chosen to share part of a costly, multi-study clinical program's funding while keeping rights and operational control. The announcement does not say Pfizer lacked the cash to run the trials. It does specify potential payments to Blackstone if the named approval and sales milestones are met, so any near-term financial flexibility carries a contingent future cost.

Pfizer obesity drug: Blackstone's $1.5 billion funds trials, not a takeover

Keep reading with a free account